Rxcurve
HCPCS Q9999 · per 1 MG

Inj ustekinumab-aauz 1 mg

Products billed under this code include Otulfi, Ustekinumab-AAUZ.

Payment limit per 1 MG, by effective quarter, 4Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under Q9999

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Otulfi FreseniUS Kabi USA, LLC 65219-0822-05 45 $596.07
Otulfi FreseniUS Kabi USA, LLC 65219-0824-01 45 $596.07
Otulfi FreseniUS Kabi USA, LLC 65219-0826-26 90 $1,192.14
Otulfi FreseniUS Kabi USA, LLC 65219-0828-05 130 $1,721.98
Ustekinumab-AAUZ FreseniUS Kabi USA, LLC 65219-0862-01 45 $596.07
Ustekinumab-AAUZ FreseniUS Kabi USA, LLC 65219-0866-26 90 $1,192.14

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $13.246 +$0.092 1 MG Inj ustekinumab-aauz 1 mg v1, posted September 17, 2026
3Q26 $13.154 −$0.139 1 MG Inj ustekinumab-aauz 1 mg v1, posted September 15, 2026
2Q26 $13.293 −$19.664 1 MG Inj ustekinumab-aauz 1 mg v1, posted September 15, 2026
1Q26 $32.957 −$0.131 1 MG Inj ustekinumab-aauz 1 mg v1, posted September 15, 2026
4Q25 $33.088 – 1 MG Inj ustekinumab-aauz 1 mg v1, posted September 8, 2026

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files